Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

NCT05982756 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Bortezomib
Acute Myeloid Leukemia

Interventions

DRUG: DAG pre-excitation regimen with Bortezomib

Sponsor

Zhongnan Hospital